Johnson & Johnson complete friendly takeover of Crucell

February 22, 2011

Pharmaceutical and health care giant Johnson & Johnson announced Tuesday the successful completion of a friendly takeover of Dutch vaccine maker Crucell, for about 1.75 billion euros ($2.37 billion).

"Johnson & Johnson and Crucell today announce that Johnson & Johnson has completed the tender offer for Crucell," the companies said in a joint statement.

Johnson & Johnson, which employs 114,000 people, has said it intends to retain Crucell's management and staff and to keep the headquarters at Leiden in the western Netherlands.

Johnson & Johnson, which now owns more than 95 percent of Crucell's capital announced a supplementary offer period from Wednesday until March 8.

The health care giant first announced its intention to buy up Crucell last October for 24.75 euros per share.

The European Commission authorised the late last month, seeing no competition problems.

Crucell, which employs 1,300 people, produced more than 115 million doses of vaccine in 2009 for distribution in about 100 countries, mostly developing nations.

Explore further: Summer time and the living is breezy

Related Stories

Summer time and the living is breezy

June 6, 2006

The U.S. hurricane season is under way and for many people in areas hit hard by 2005's hurricanes, it's going to be an uneasy summer.

Farmers relying on roundup lose some of its benefit

April 14, 2009

( -- Roundup Ready crops have made weed control much easier for farmers, but a new study shows their reliance on the technology may be weakening the herbicide's ability to control weeds.

Johnson & Johnson plans to buy Dutch vaccine group

September 17, 2010

US cosmetics and pharmaceutical giant Johnson & Johnson said on Friday it intended to acquire a Dutch vaccine maker Crucell which is active in developing countries for about 1.75 billion euros.

Johnson & Johnson, Crucell biotech announce takeover

October 6, 2010

Pharmaceutical and health care giant Johnson & Johnson has reached a deal with Dutch biotechnology vaccine group Crucell to buy 82.5 percent of Crucell for about 1.75 billion euros, the two firms said on Wednesday.

Recommended for you

How the finch changes its tune

August 3, 2015

Like top musicians, songbirds train from a young age to weed out errors and trim variability from their songs, ultimately becoming consistent and reliable performers. But as with human musicians, even the best are not machines. ...

Machine Translates Thoughts into Speech in Real Time

December 21, 2009

( -- By implanting an electrode into the brain of a person with locked-in syndrome, scientists have demonstrated how to wirelessly transmit neural signals to a speech synthesizer. The "thought-to-speech" process ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.